|
1) Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344: 699-709
|
|
|
|
2) Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286: 1869-78
|
|
|
|
|
|
3) Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238-47
|
|
|
|
|
|
4) Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007; 109: 3161-72
|
|
|
|
|
|
5) Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 2006; 12: 1278-85
|
|
|
|
|
|
6) Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007; 13: 1349-58
|
|
|
|
|
|
7) White TC, Berny MA, Tucker EI, et al. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost. 2008; 6: 995-1002
|
|
|
|
|
|
8) Kim DH, Iijima H, Goto K, et al. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem. 1996; 271: 8373-80
|
|
|
|
|
|
9) Yang XV, Banerjee Y, Fernandez JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A. 2009; 106: 274-9
|
|
|
|
|
|
10) Heeb MJ, Rosing J, Bakker HM, et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A. 1994; 91: 2728-32
|
|
|
|
|
|
11) Sere KM, Janssen MP, Willems GM, et al. Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. Biochemistry. 2001; 40: 8852-60
|
|
|
|
|
|
12) Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006; 103: 3106-11
|
|
|
|
|
|
13) Ndonwi M, Broze G, Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost. 2008; 6: 1044-6
|
|
|
|
|
|
14) Garcia de Frutos P, Alim RI, Hardig Y, et al. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood. 1994; 84: 815-22
|
|
|
|
|
|
15) Maurissen LF, Thomassen MC, Nicolaes GA, et al. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood. 2008; 111: 3034-41
|
|
|
|
|
|
16) Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood. 2009; 114: 2307-14
|
|
|
|
|
|
17) Lay AJ, Donahue D, Tsai MJ, et al. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood. 2007; 109: 1984-91
|
|
|
|
|
|
18) Li W, Zheng X, Gu JM, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood. 2005; 106: 2716-22
|
|
|
|
|
|
19) Kimura R, Honda S, Kawasaki T, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood. 2006; 107: 1737-8
|
|
|
|
|
|
20) Kinoshita S, Iida H, Inoue S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005; 38: 908-15
|
|
|
|
|
|
21) Kimura R, Sakata T, Kokubo Y, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost. 2006; 4: 2010-3
|
|
|
|
|
|
22) Miyata T, Sato Y, Ishikawa J, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res. 2009; 124: 14-8
|
|
|
|
|